Unprecedented surge in Irish exports this year was almost entirely driven by shipments of drug ingredients for Eli Lilly

Danish drugmaker expects sales and profit growth at lower end of its guidance this year

Wegovy maker’s top investor proposes international board overhaul

The company’s shares have nearly halved since the start of the year and expects slower growth this year

Williams is not the first sportsperson to promote GLP-1 weight loss medication but she is the most high profile and easily the most significant

GLP-1 agonists such as Ozempic and Wegovy have a lot of promise

Union advises people to only purchase drugs from registered pharmacies

Novo Nordisk has now lost two-thirds of its value in little over a year

Pharma companies also volatile in wake of letters from US president to 17 of them demanding lower prices

Pharmaceutical giants in Europe brace themselves for a tariffs fight that is likely still to come

Health officials begin a study into potential side-effects of drugs such as Mounjaro, Wegovy and Ozempic

‘Significant number of non-compliances’ by pharmaceutical firm behind weight loss drugs

Investor expectations, it seems, are harder to manage than blood sugar

First-quarter sales rise 18 per cent but Danish pharma group blames custom preparations at pharmacies for weaker take-up

Prof Donal O’Shea hails breakthrough and says it may play key role in reshaping treatments

Weight loss drug is not yet approved for reimbursement under Drug Payment Scheme or for medical card patients

Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now at least

Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year

Danish obesity drug giant looking at whether its semaglutide drug can reduce cravings associated with addiction

Glanbia's once-popular weight-loss product has fallen out of favour with consumers